Biologics and Biostimulants in 2025

Despite $3.1 billion in sales, venture investment in biostimulants fell by 86% in 2024. Why? Because consistency and scalability remain unresolved challenges across the value chain.

What’s holding back adoption?

• Rising production and formulation costs
• Performance variability across soils, crops, and climates
• Limited distribution and cold-chain logistics
• Knowledge and technical-support gaps
• Fragmented regulations across markets

Each factor increases risk, cost, or uncertainty — eroding confidence in long-term ROI.

Still, progress is being made. New formulation science, shelf-life technologies, and packaging innovations (like high-barrier multilayers, MAP, or active antimicrobial coatings) are extending product durability and cutting waste.

Longer shelf lives alone can raise profit potential by over 30% through reduced spoilage and better inventory turnover.

When combined with improved field data, predictive agronomy, and precision farming tools, biologics are moving closer to dependable performance— one innovation at a time.

Sustainable input technologies aren’t a passing phase.

They are the future’s foundation— bridging productivity with ecological balance.

🌱 The best is truly yet to come for biologics, biostimulants, and sustainable crop nutrition.